Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Clin Endocrinol (Oxf) ; 86(2): 286-296, 2017 Feb.
Article in English | MEDLINE | ID: mdl-27678251

ABSTRACT

OBJECTIVE: For 'asymptomatic carriers' of the succinate dehydrogenase subunit B (SDHB) gene mutations, there is currently no consensus as to the appropriate modality or frequency of surveillance imaging. We present the results of a surveillance programme of SDHB mutation carriers. DESIGN: Review of clinical outcomes of a surveillance regimen in patients identified to have an SDHB gene mutation, based on annual MRI, in a single UK tertiary referral centre. PATIENTS: A total of 92 patients were identified with an SDHB gene mutation. a total of 27 index patients presented with symptoms, and 65 patients were identified as asymptomatic carriers. MEASUREMENTS: Annual MRI of the abdomen, with alternate year MRI of the neck, thorax and pelvis. Presence of an SDHB-related tumour included paraganglioma (PGL), phaeochromocytoma (PCC), renal cell carcinoma (RCC) and gastrointestinal stromal tumour (GIST). RESULTS: A total of 43 PGLs, eight PCCs and one RCC occurred in the 27 index patients (23 solitary, four synchronous, five metachronous). A further 15 SDHB-related tumours (11 PGLs, three RCCs, one GIST) were identified in the asymptomatic carriers on surveillance screening (25% of screened carriers): 10 on the first surveillance imaging and five on subsequent imaging 2-6 years later. A total of 11 patients had malignant disease. CONCLUSIONS: SDHB-related tumours are picked up as early as 2 years after initial negative surveillance scan. We believe the high malignancy rate and early identification rate of tumours justifies the use of 1-2 yearly imaging protocols and MRI-based imaging could form the mainstay of surveillance in this patient group thereby minimizing radiation exposure.


Subject(s)
Epidemiological Monitoring , Heterozygote , Mutation , Succinate Dehydrogenase/genetics , Adolescent , Adult , Child , Cohort Studies , Female , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Neoplasms/diagnostic imaging , Neoplasms/genetics , Neoplasms/pathology , United Kingdom/epidemiology , Young Adult
2.
Horm Res ; 72(3): 190-6, 2009.
Article in English | MEDLINE | ID: mdl-19729952

ABSTRACT

Positron emission tomography (PET) with (18)F-fluorodeoxy-glucose indicates metabolically active tissue. When investigating enhancing intracranial tumours, we have suggested that PET positivity might suggest an intracranial germ cell tumour (IGCT). Here, we present a case with dicentric IGCT where PET was initially discordant between the lesions and where PET then became negative despite clearly aggressive clinical behaviour. A cautionary note is introduced with respect to the interpretation of negative (18)F-FDG PET when investigating enhancing intracranial lesions.


Subject(s)
Brain Neoplasms/diagnostic imaging , Neoplasms, Germ Cell and Embryonal/diagnostic imaging , Positron-Emission Tomography/methods , Antineoplastic Combined Chemotherapy Protocols , Brain Neoplasms/diagnosis , Brain Neoplasms/therapy , Fatal Outcome , Fluorodeoxyglucose F18 , Humans , Magnetic Resonance Imaging , Male , Neoplasm Recurrence, Local/diagnostic imaging , Neoplasms, Germ Cell and Embryonal/diagnosis , Neoplasms, Germ Cell and Embryonal/therapy , Pinealoma/diagnosis , Radiopharmaceuticals , Salvage Therapy , Soft Tissue Neoplasms/diagnostic imaging
SELECTION OF CITATIONS
SEARCH DETAIL
...